Brief: AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile
BRIEF-AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile Aug 10 (Reuters) - AbCellera Biologics Inc. ABCL.O:
ABCELLERA ANNOUNCES POSITIVE TOP-LINE PHASE 2 CLINICAL TRIAL RESULTS FOR ABCL635, DEMONSTRATING SIGNIFICANT REDUCTION IN FREQUENCY AND SEVERITY OF VASOMOTOR SYMPTOMS AND A FAVORABLE TOLERABILITY PROFILE
ABCELLERA BIOLOGICS - PHASE 2 RESULTS SHOW BEST-IN-CLASS REDUCTIONS IN VASOMOTOR SYMPTOMS AFTER SINGLE DOSE
ABCELLERA BIOLOGICS - ABCL635 SIGNIFICANTLY IMPROVES SLEEP AND PATIENT GLOBAL IMPRESSION OF CHANGE
ABCELLERA BIOLOGICS - ABCL635 DEMONSTRATES FAVORABLE TOLERABILITY PROFILE
ABCELLERA BIOLOGICS - STUDY MEETS PRIMARY EFFICACY ENDPOINTS WITH SIGNIFICANT REDUCTIONS AT WEEK 4
ABCELLERA BIOLOGICS - ABCL635 WELL-TOLERATED WITH NO SERIOUS OR SEVERE ADVERSE EVENTS
Source text: ID:nBwbWgTQra
Further company coverage: ABCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce